

Henry Ford Health

Henry Ford Health Scholarly Commons

Radiation Oncology Articles

Radiation Oncology

3-15-2021

Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology

Carri K. Glide-Hurst

Percy Lee

Adam D. Yock

Jeffrey R. Olsen

Minsong Cao

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/radiationoncology_articles

Recommended Citation

Glide-Hurst CK, Lee P, Yock AD, Olsen JR, Cao M, Siddiqui F, Parker W, Doemer A, Rong Y, Kishan AU, Benedict SH, Li XA, Erickson BA, Sohn JW, Xiao Y, and Wuthrick E. Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology. *Int J Radiat Oncol Biol Phys* 2021; 109(4):1054-1075.

This Article is brought to you for free and open access by the Radiation Oncology at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Radiation Oncology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

Authors

Carri K. Glide-Hurst, Percy Lee, Adam D. Yock, Jeffrey R. Olsen, Minsong Cao, Farzan Siddiqui, William Parker, Anthony Doemer, Yi Rong, Amar U. Kishan, Stanley H. Benedict, X. Allen Li, Beth A. Erickson, Jason W. Sohn, Ying Xiao, and Evan Wuthrick

Physics Contribution

Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology



Carri K. Glide-Hurst, PhD,^{*} Percy Lee, MD,[†] Adam D. Yock, PhD,[‡] Jeffrey R. Olsen, MD,[§] Minsong Cao, PhD,^{||} Farzan Siddiqui, MD, PhD,[¶] William Parker, MS,[#] Anthony Doemer, MS,[¶] Yi Rong, PhD,^{**} Amar U. Kishan, MD,^{||} Stanley H. Benedict, PhD,^{**} X. Allen Li, PhD,^{††} Beth A. Erickson, MD,^{††} Jason W. Sohn, PhD,^{‡‡} Ying Xiao, PhD,^{§§} and Evan Wuthrick, MD^{|||}

^{*}Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin;

[†]Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas;

[‡]Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee;

[§]Department of Radiation Oncology, University of Colorado-Denver, Denver, Colorado; ^{||}Department

of Radiation Oncology, University of California-Los Angeles, Los Angeles, California; [¶]Department of

Radiation Oncology, Henry Ford Cancer Institute, Detroit, Michigan; [#]Department of Radiation

Oncology, McGill University, Montreal, Quebec, Canada; ^{**}Department of Radiation Oncology,

University of California-Davis, Sacramento, California; ^{††}Department of Radiation Oncology, Medical

College of Wisconsin, Milwaukee, Wisconsin; ^{‡‡}Department of Radiation Oncology, Allegheny Health

Network, Pittsburgh, Pennsylvania; ^{§§}Department of Radiation Oncology, University of

Pennsylvania, Philadelphia, Pennsylvania; and ^{|||}Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida

Received Mar 12, 2020. Accepted for publication Oct 19, 2020.

Corresponding author: Carri K Glide-Hurst, PhD; E-mail: glidehurst@humonc.wisc.edu

Disclosures: S.H.B., Y.R., and Y.X. have nothing to disclose. M.C. reports personal fees from ViewRay Inc and Varian Inc, outside the submitted work. A.D. reports honoraria and lecturing for ViewRay Inc. B.A.E. reports departmental research support from Elekta, outside the submitted work. C.K.G.-H. reports travel and honoraria for speaking engagements from ViewRay Inc; advisory board membership and a master research agreement from Philips Healthcare; grants from NIH, National Cancer Institute of the National Institutes of Health under Award Number R01CA204189; and a research agreement from Modus Medical, outside the submitted work. A.U.K. reports honoraria from and consulting for Varian Medical Systems; a grant and honoraria from ViewRay Inc; advisory board membership for Janssen; and consulting fees from Intelligent Automation, outside the submitted work. P.L. reports personal fees and nonfinancial support from ViewRay Inc; grants, personal fees, and nonfinancial support from AstraZeneca Inc; and personal fees and nonfinancial support from Varian Inc, outside the submitted work. X.A.L. reports

research grants to institution from Elekta AB, Manteia Med, and Siemens Med, outside the submitted work. In addition, X.A.L. has a patent/license on ART techniques. J.R.O. reports in the past (>48 months ago) receiving industry research funding in support of MR guided radiation therapy and travel/speaking fees to give presentations on MR guided radiation therapy. W.P. reports being an employee of McGill University Health Centre, outside the submitted work. F.S. reports honoraria for talks and lectures from Varian Medical Systems Inc and for site surveys from the American College of Radiology, during the conduct of the study. E.W. reports personal fees from Varian and Sanofi/Regeneron, outside the submitted work. A.D.Y reports grants and personal fees from Varian Medical Systems, outside the submitted work; In addition, A.D.Y has a patent pending adaptive radiotherapy phantom. J.W.S. discloses grants from NIH under award numbers R21DE028690 and R01CA187053 outside of the submitted work.

Supplementary material for this article can be found at <https://doi.org/10.1016/j.ijrobp.2020.10.021>.

The integration of adaptive radiation therapy (ART), or modifying the treatment plan during the treatment course, is becoming more widely available in clinical practice. ART offers strong potential for minimizing treatment-related toxicity while escalating or de-escalating target doses based on the dose to organs at risk. Yet, ART workflows add complexity into the radiation therapy planning and delivery process that may introduce additional uncertainties. This work sought to review presently available ART workflows and technological considerations such as image quality, deformable image registration, and dose accumulation. Quality assurance considerations for ART components and minimum recommendations are described. Personnel and workflow efficiency recommendations are provided, as is a summary of currently available clinical evidence supporting the implementation of ART. Finally, to guide future clinical trial protocols, an example ART physician directive and a physics template following standard NRG Oncology protocol is provided. © 2020 Published by Elsevier Inc.

Introduction

Adaptive radiation therapy (ART) was introduced in the late 1990s as “a closed loop radiation treatment process where the treatment plan can be modified using a systematic feedback of measurements with the intention to improve radiation treatment by systematically monitoring treatment variations and incorporating them to reoptimize the treatment plan early on during the course of treatment.”¹ By accounting for changes in the patient’s anatomy during the treatment course, isotoxic-based radiation therapy (escalating or de-escalating target doses to maintain a constant, acceptable risk of clinical toxicity based on the dose to organs at risk [OARs]) has been demonstrated.²⁻⁴ ART may be implemented to address patient-specific treatment variations, including systematic changes in weight, tumor, and organ geometric and biological response, as well as stochastic variations such as organ deformation, filling change, and respiration and peristaltic motion. These variations may occur at different time scales ranging from seconds to hours to days. As a result, the implementation of ART is often binned into 3 major classes: (1) offline between treatment fractions, (2) online immediately before a treatment fraction, and (3) real-time during a treatment fraction, with major steps outlined in Figure 1.

Offline ART mostly addresses systematic and progressive changes that occur during the treatment course, such as patient weight loss and tumor morphologic changes.⁵ For offline ART, adjustments to a patient’s treatment plan parameters based on these observed changes are modified after the current treatment fraction and typically follow the same clinical workflow as regular initial treatment planning. Repeat simulation may be required if the acquired in-room image is not sufficient for treatment planning, followed by contouring, planning, and patient-specific quality assurance (PSQA). The resultant new treatment plan is reviewed by the physician and then implemented in subsequent delivery sessions. Offline ART has been shown in prospective clinical trials in the prostate, head and neck, and lung to yield improved target coverage and OAR sparing.^{2,6-9}

Many treatment variations, such as interfractional target and organ displacement, particularly in the abdomen and pelvis, and deformation of OARs will occur during a shorter time scale; thus, offline ART is not sufficient to account for these variations. Online ART is a process in which the patient’s treatment plan is adjusted before treatment delivery to account for temporal and stochastic changes detected in a single treatment fraction while the patient remains in the treatment position. As a result, online ART requires imaging, rapid replanning, plan review, and an acceptable form of PSQA. Although resource and time intensive, online ART has shown promise for conventional and stereotactic body radiation therapy to enable better OAR sparing and improved target coverage, particularly in the head and neck,¹⁰ abdomen,¹¹⁻¹⁴ and pelvis,¹⁵⁻¹⁸ and more recently for ultracentral lung cancer.¹⁹ Promising data have emerged for using daily online magnetic resonance (MR)-guided ART for localized prostate cancer, showing a low incidence of early gastrointestinal and genitourinary toxicities in clinician- and patient-reported outcomes.²⁰ A multi-institutional prospective phase 2 study of stereotactic MR-guided on-table ART with real-time respiratory gating for patients with locally advanced pancreatic cancer is currently enrolling to evaluate toxicity, overall/progression-free survival, and patient-reported quality of life (QOL) using daily online ART.²¹ Daily target dose escalation has also been proposed when OARs are in a favorable location, although clinical evidence is still emerging.

To account for variations that occur within a treatment fraction, such as respiration, internal status changes, and peristalsis motion, real-time ART has been introduced, in which the treatment plan is automatically adapted during treatment delivery without operator intervention. Real-time ART may be performed through treatment gating, dynamic tracking by the treatment machine (eg, CyberKnife [Accuray, Sunnyvale, CA] or Vero²² [Brainlab, Munich, Germany] systems), by the multileaf collimators (MLCs), and intrafraction replanning, although such an approach typically requires continuous imaging with constant replanning and rapid dose calculation.²³⁻²⁵ The CyberKnife Stereotactic Radiosurgery System with Synchrony Respiratory Tracking System dynamically tracks




Fig. 1. Typical elements in adaptive radiation therapy workflows, including online, offline, and real-time approaches.

tumors that move during respiration via an external to internal motion correlation model updated throughout treatment using x-ray imaging.^{26,27} More recently, the Radixact (Accuray), a next-generation helical tomotherapy system, has integrated intrafraction motion management based on the Synchrony to predict motion based on implanted fiducials or the tumor itself.²⁸ Real-time ART has also been realized using simultaneous intrafraction monitoring for target identification and MLC tracking to align the beam to the target for stereotactic body radiation therapy (SBRT) prostate cases using a standard linear accelerator (linac).²⁹

In addition to classification based on the time domain, ART may be characterized as anatomically or biologically driven based on treatment variations. Biologically guided ART holds great promise because changes at physiologic and molecular levels usually occur before anatomic change, leading to early treatment adaption. Patient-specific biological changes during treatment have been shown to correlate with clinical outcomes and toxicity profiles, suggesting strong clinical benefits of biological-guided ART in personalized treatment. However, biologically guided ART remains limited in clinical practice. The majority of the current studies focus on adjustment of target volumes based

on functional imaging obtained during the treatment course, with a comprehensive review of biologically guided ART provided in the literature.³⁰ Several ongoing clinical trials are underway (e.g., NCT02031250, NCT03416153, NCT03224000, and NCT01504815) that aim to investigate functional subvolume boosting and dose scheme changes based on functional imaging.

Regardless of the class of ART implementation or combinations thereof, the increasing interest in ART along with emerging vendor-provided products and workflows will undoubtedly increase ART utilization. Yet, ART introduces complexities into the clinical workflow that will necessitate rigorous benchmarking and evaluation. This need will become even greater as ART is applied to clinical trials, in which safe and consistent implementation is of paramount importance to ensure high fidelity in trial outcomes. Overall, this work describes considerations pertinent to the implementation of ART techniques and establishes a foundation for the safe and effective implementation of ART both in conventional clinical contexts and in clinical trials.

Technological Considerations for ART

Image acquisition

Performing the necessary steps for ART requires adequate information for tumor/OAR delineation, accurate dose calculation, and sufficient image quality. [Table 1](#) summarizes the major imaging modalities used in different ART workflows at the present time, their advantages and disadvantages, and special considerations for their implementation, accompanied by a consensus subjective grading system for the merits of each modality. Although [Table 1](#) highlights the current imaging modalities being implemented, new image reconstruction algorithms are emerging that may have implications for ART performance, such as iterative cone beam computed tomography (iCBCT), which has shown promise for improved image quality and more complete fields of view (FOVs) than conventional CBCT.^{31,32} Recently, Ethos (Varian, Palo Alto, CA) was introduced; it integrates iterative CBCT for dose calculation on the anatomy of the day, with clinical integration efforts ongoing.³³ Furthermore, with the recent trend toward hypofractionated treatment regimens, imaging doses are expected to become less of a concern in the future.

Deformable image registration

Deformable image registration (DIR) is an important step commonly used during ART to account for changes in the shape and size of internal organs between the initial and adaptive planning images acquired during the treatment course. For offline ART, DIR is used as needed. The adaptive planning image may include high-quality

computed tomography (CT) images, images that were used for image guided radiation therapy (IGRT) (ie, CBCT and magnetic resonance imaging [MRI]), or an interim functional image such as a positron emission tomography (PET)-CT or MRI. For online ART workflows, DIR is often used at every fraction before treatment delivery for tasks such as deforming contours or performing electron density mapping between the initial planning data set and the daily images used for patient positioning. At present, many treatment planning vendors and standalone image registration software suites offer DIR and ART workflows, as summarized in [Table 2](#).

Deformation vector fields (DVF), or the voxel-by-voxel 3D transformation matrix obtained from DIR,³⁴ are often applied for tasks such as contour propagation, plan adjustment, and fractional dose accumulation.^{23,35} Therefore, any errors introduced in the image deformation process may be propagated downstream in the ART workflow. Error and uncertainty originating from DIR often arise from the image quality of the 2 input images, inaccuracy of the DIR algorithms, and any parameter selection or manual adjustment during the registration process. For online and offline ART, the input images include the original planning data set (the moving image) and the stationary image acquired during treatment. It is important that both the moving and stationary image be evaluated for image quality because errors from the input images often arise from image artifacts (eg, noise, blur caused by motion, image truncation) or image distortion, such as in MRI.

In 1998, Maintz and Viergever³⁶ summarized image registration variables and categorized them using 9 criteria, including dimensionality, nature of the registration basis, domain of the transformation, degree of interaction, optimization procedure, image modalities, involved subjects, and body sites. Twenty years later, these classifications still hold, with minor revisions.³⁷ All of these variables introduce various degrees of errors and uncertainties during DIR that are convoluted in the DVF obtained from image deformation, which will then be applied for contour mapping and dose deformation/accumulation tasks. Therefore, it is essential for the end user to perform validation of the DIR algorithm.

However, direct quantitative validation of DIR using the DVF has proven difficult owing to the lack of ground truth. Recently, AAPM Task Group 132 (TG-132) has provided guidelines on using qualitative and quantitative measures for evaluating image registration accuracy.³⁴ Qualitative methods include visual checking with various display methods, including image-to-image comparison with or without mapped contour/structure overlays. Quantitative metrics include target registration error, mean distance to agreement, the Dice similarity coefficient (DSC), Jacobian matrix (identifying local volume changes such as expansion or contraction that may indicate erroneous regions of interest), and consistency (or the independence of the algorithm to the direction of the registration). TG-132 has provided expected tolerances to each of these metrics based

Table 1 Image modality considerations for online and offline ART implementations

ART imaging modality considerations	CT (on rails or simulation)	CBCT	MVCT	MRI	PET
Image quality and contrast—soft tissue differentiation	Diagnostic quality. Same as planning CT scan ****	Good contrast for large-density differences such as bone/ tissue/air. Scatter significantly decreases contrast. ***	Good contrast for large-density differences such as bone/ tissue/air. Scatter significantly decreases contrast. **	Excellent soft tissue contrast *****	No soft tissue differentiation but provides quantitative functional information ***
Spatial resolution	Same as planning CT scan—submillimeter, can be limited longitudinally *****	Same as planning CT scan—submillimeter, longitudinally typically 1 mm ****	Same as planning CT scan—submillimeter, longitudinally typically 2 mm ****	Similar to planning CT scan—submillimeter, longitudinally typically 1 mm ****	Typically few mm in each direction PET, depends on body site ***
Motion artifacts	Fast scan but motion must be managed to avoid artifacts	Long scan times prone to motion artifacts	Long scan times prone to motion artifacts	Scan times can be long or short, prone to motion artifacts	Very long scan times, prone to blurring from motion
Clinical motion management solutions	Yes ****	Yes **	No **	Yes ***	No *
Reconstruction artifacts	Prone to hardening artifacts from high Z materials or elongated body shape, motion ***	Same artifacts as CT, as well as scatter, ring, aliasing, and misalignment artifacts ***	Same artifacts as CT, zipper artifacts ***	Susceptibility, motion, distortion **	Same artifacts as CT, attenuation correction, motion, CT reconstruction and partial volume **
Geometry Anatomy	Anatomy changes from CT, organ localization ****	Anatomy changes, organ localization ***	Anatomy changes, organ localization ***	Anatomy changes, organ localization *****	Metabolic uptake changes ****
FOV limitations	60 cm FOV ****	Up to 50 cm FOV, large FOV results in poor image quality ***	Up to 50 cm FOV, large FOV results in poor image quality ***	Up to 50 cm FOV ****	Up to 70 cm FOV ****

Patient position issues	Same as planning CT scan ****	Can affect image quality depending on position on treatment couch ***	Can affect image quality depending on position on treatment couch ***	Bore size may limit patient position, coil placement may limit use of accessories ***	May not be same as simulation setup, PET scan bore size may limit patient position ****
Truncated structures	Same as planning CT scan	FOV limitations may truncate structures	FOV limitations may truncate structures	FOV limitations may truncate structures and external contour	Same as planning CT scan
Tracking organ motion	Not available during treatment *	Not available during treatment *	Not available during treatment *	Available ****	Not available during treatment *
Density HU table management	Same as planning CT scan *****	Can build custom HU table 1%-2% accuracy in dose calculation *****	MVCT number, similar to HU table, must be monitored at high frequency ***	Not available, surrogate needed **	Same as planning CT scan if PET-CT *****
Online/offline ART Modality for online	CT on rails ***	CBCT ***	Tomotherapy able to sum plans and “dose of the day” ***	MRI-cobalt, MRI-linac ****	Under development *
Additional dose to patient	Up to 3 cGy per scan ***	Up to 10 cGy per scan **	Up to 5 cGy per scan **	Not applicable *****	Up to 3 cGy whole body plus CT dose **

Grading system: (least to most advantageous, 1* to 5*) based on consensus grading by authors.

Abbreviations: ART = adaptive radiation therapy; CBCT = cone beam computed tomography; FOV = field of view; HU = Hounsfield units; linac = linear accelerator; MVCT = megavoltage computed tomography; MRI = magnetic resonance imaging.

Table 2 Summary of currently available deformable image registration and relevant adaptive radiation therapy components

Vendor	DIR algorithm	Unimodal registration (CT, CBCT)	Multimodal registration (CT, PET, MR)	Contour propagation	Dose warping and summation	Offline ART	Online ART
Stand-alone DIR products							
MIM (v 6.8)	Free-form, Demons optical flow ^{27,28}	Yes	Yes	Yes	Yes	No	No
Velocity (v 3.2)	Multipass B-spline ²⁹	Yes	Yes	Yes	Yes	Yes*	No
Mirada (v RTX1.8)	Unimodal: free-form Multimodal: radial basis function ³⁰	Yes	Yes	Yes	Yes	Yes*	No
Treatment planning systems with DIR modules							
Raystation (v 9A)	ANACONDA, ³¹ MORFEUS ³²	Yes	Yes	Yes	Yes	Yes	No
Eclipse (v 15.6)	Unimodal: accelerated Demons ³³ Multimodal: adaptive grid-based radial basis function	Yes	Yes	Yes	Yes	Yes	No
Pinnacle (v 9.10)	Fast symmetrical Demons, salient-feature–based registration ^{34,35}	Yes	Yes	Yes	Yes	No	No
Monaco (v 5.51)	Gradient-free dense hybrid MI deformation ^{36,37}	Yes	Yes	Yes	Yes	Yes	Yes
Precision (v 2.1)	Multiorgan B-spline ³⁸	Yes	Yes	Yes	Yes	Yes	Yes
ViewRay (v 5.2.5)	Free-form Unimodal: correlation coefficient Multimodal: mutual information	Yes	Yes	Yes	No	Yes	Yes

Abbreviations: ANACONDA = ANAtomically CONstrained Deformation Algorithm; ART = adaptive radiation therapy; CBCT = cone beam computed tomography; CT = computed tomography; DIR = deformable image registration; MI = mutual information; MORFEUS = multiorgan finite element modeling algorithm; MR = magnetic resonance; PET = positron emission tomography.

* Partial offline ART functionality (no treatment planning).

on the application and image voxel dimensions. Validation of DIR performance often consists of verifying landmarks such as bifurcations or implanted markers.³⁸ In addition, subjective scoring methods for evaluating the mapped structures have been proposed.^{39,40} Phantom data sets for multiple modalities (ie, CT, CBCT, PET, and MRI) have been made available by TG-132 for DIR validation and are currently under evaluation by the NRG Image Deformation Working Group. Publicly available data sets have also been created for image registration validation, including brain MR images,⁴¹ head and neck CT images,⁴² prostate CT images,⁴³ and thoracic CT and 4DCT images,⁴³⁻⁴⁶ to benchmark DIR performance.

Dose accumulation and tracking

ART may yield significant improvements in accommodating tumor and OAR changes during the treatment course when the original planning data set is not fully representative of the anatomy of the day. However, as the anatomy

and corresponding contours change, the initial dose calculated by using the planning data set may have limited accuracy and may not continue to represent the actual delivered dose. For example, in a head and neck cohort of 13 patients, a dose reduction of 0.2 to 7.4 Gy was observed in the planning target volume (PTV) coverage (D95%) with increased maximum doses of 0.6 to 8.1 Gy and 0.2 to 15.4 Gy in the brain stem and cord, respectively.⁴⁷ Recently, MR-guided ART has shown that for pancreas SBRT, the dose to the duodenal loop would increase by up to 6 Gy whereas the PTV coverage would be reduced by up to 4.5% if the plan were not adapted.⁴⁸ Therefore, ART calls for an updated 3D data set representing the current anatomy, an adaptive plan tailored to the anatomy change, and, ideally, an accurate summary of the “as delivered” dose. Here, “as delivered” refers to updated dose reporting that takes into account tumor and adjacent OAR anatomy changes, with a determined dose (dose-volume histogram) that was delivered to the patient. To provide such an updated delivered dose, a voxel-by-voxel dose accumulation for each delivery timepoint needs to be determined by deforming the dose

based on the calculated DVF from DIR over the treatment course with the dose warped back to the initial planning CT for dose accumulation for the total fractions to date.⁴⁹

An alternative approach to obtain the daily delivered dose is to deform the initial planning data set to match the daily IGRT image (ie, CBCT, megavoltage computed tomography, CT on rails, or MRI) for calculating the “dose of the day.” By applying DIR, the dose calculated based on a deformed planning CT has been shown have 95% of the voxels agree at 2 mm/2% with the resimulated CT dose,⁵⁰ which may be considered clinically acceptable. This methodology of deforming the adapted planning image yields improved dose estimation compared with conventional dose calculations based on the rigid registration of the planning CT or directly on the CBCT itself.

Nevertheless, estimating the cumulative dose is still highly dependent on the choice of DIR algorithm and the underlying image quality. For online ART, ideally, a fully integrated treatment planning, imaging, and dose delivery system accompanied by an optimized DIR algorithm would be needed to implement this computationally intense adaptive workflow in an efficient fashion. The calculated “dose of the day” for each fraction can be warped back to the reference CT (ie, the planning CT) or MRI data set and summed to obtain the estimated accumulated dose. The accuracy of this accumulated dose is highly dependent on the DVF generated from the initial steps of image deformation. A wide range of DIR accuracy has been reported, from <1 mm up to 10 mm depending on the disease site and DIR algorithm used.^{41,43,51} Corresponding dose deviations illuminated via accumulation may have clinical impact, depending on the cancer site, image modality and quality, DIR algorithm, parameter choices, dose evaluation metrics (eg, mean, maximum, minimum, D95), organ volume/motion, and other factors.⁵²⁻⁵⁵

The accuracy of dose warping and accumulation depends on the accuracy of the DVF, which may be limited by internal target changes (ie, shrinkage or growth) and movement of the adjacent organs that may challenge boundary detection. Mass changes are a particular challenge for DIR, and other methods to accommodate them, such as integrating models of tumor regression,⁵⁶ have been described in the literature. To date, limited studies provide reliable quality assurance (QA) methods to ensure the accuracy of dose warping and accumulation for patient data sets; thus, caution must be taken when applying to ART decision-making.

Rapid replanning

Replanning cases for ART involves consideration of the strategy (offline vs online), timely delineation of targets and/or OARs, the time it takes to replan, and the clinical criteria as to what necessitates the adaptation. RTOG 1106 is an example of an offline ART clinical trial schema for advanced stage lung cancer in which the experimental arm

includes a PET/CT and CT resimulation acquired after fraction 18, offline replanning, and a new treatment plan beginning on fraction 22 to allow sufficient time for the development and QA of the adapted plan.⁵⁷ A recently published offline ART protocol for oropharynx cancer included weekly adaptation using geometric criteria (when the gross tumor volume [GTV] shrinkage exceeded 2 mm) via CT and MR simulation data acquired at intervals of 5 ± 2 fractions.⁵⁸ An offline adaptive scheme using CBCT-generated contours from the initial 6 fractions of radiation therapy for prostate cancer has been used to generate average positions of the CTV and rectum, with $\sim 7 \pm 0.5$ hours additional time needed to perform the additional replanning.⁵⁹ Offline ART workflow solutions are becoming commercially available to help in the decision-making process regarding adaptation. For example, Accuray's PreciseART treatment planning system allows for automated dose monitoring and volume-based statistics that may be reviewed offline to assess the need for adaptation, with example cases taking 2 to 8 fractions between plan evaluation and treating with a new adapted plan.⁶⁰ The total time required for offline ART will depend on several factors, including the amount of multimodality imaging needed, total number of organs that need to be recontoured, dose accumulation/plan evaluation, PSQA if warranted, and any treatment planning dose constraint challenges that may be introduced.

To facilitate online ART, contours required for replanning must be generated rapidly while the patient is on the treatment table. Strategies to expedite recontouring have included implementing rigid or DIR to propagate delineated volumes from the initial simulation images or previous fractions to the daily image. Another strategy is to perform manual recontouring limited to regions in close proximity to the target volume, such as in an MR-guided online ART scenario in the abdomen where only the OARs within a 3-cm expansion of the PTV are delineated.^{61,62} The rationale for using a subset of the OAR volume is that OAR dose tolerances are often expressed as a small-volume dose constraint (typically D0.5cc), and presumably these will be located close to the target volume. Recent results presented for MR-guided online ART showed clinically acceptable contouring times (median, 9 minutes; range, 2-24 minutes) to allow for daily adaptation in a clinical trial setting using this contouring strategy.¹¹ Recent efforts using rapid auto-contouring approaches such as deep learning^{63,64} are emerging and offer great potential to facilitate more efficient online ART. One such example is Varian's Ethos online x-ray-based ART solution that uses neural networks involving a large library of images and ground truth contours to autosegment the anatomy of the day.³³

Aside from recontouring, plan reoptimization must also be performed quickly for online ART. For head and neck cancer cases using CT on rails and a conventional linac, an online ART workflow for plan reoptimization can be completed in 5 to 8 minutes.¹⁰ To perform a more expedited optimization, one strategy includes combining all OARs

into a single optimization structure to decrease the total objectives that need to be achieved by the optimizer and thereby simplify the optimization process. This also makes for a more robust planning approach because the achieved dose distribution will be less sensitive to expected daily changes, although caution must be exercised to ensure all necessary OARs are included in the optimization. Sophisticated workflows for online optimization have been implemented, including using an artificial neural network that provided robust parameters that consistently met the OAR constraints, compared with a failure rate of 36% of fractions in which a conventional optimization approach was used.⁶² Reoptimization times ranging from 10 to 223 seconds for full reoptimization of lumbar spine bone metastases have been achieved on a 1.5T MR linac.⁶⁵

To ensure accurate dose calculation, an accurate CT number (and, hence, electron density) is required. In an MR-guided ART workflow, multimodality DIRs between the CT, daily electron density map, and MRI may severely warp the images, as shown in Figure 2, and introduce uncertainties in dose calculation. This also requires substantial personnel effort to fix the underlying electron density map via manual overrides of air and tissue. Indeed, the evaluation and correction of electron density maps is a rate-limiting QA step requiring significant resources in many MR-only and ART workflows,⁶⁶⁻⁶⁸ and thus appropriate QA steps are required to address these uncertainties during online replanning.

Overall, performing the entire online MR-guided ART process including IGRT, recontouring, replanning, and QA has been reported to have a median on-table time of ~80 minutes per fraction (range, 36-160 minutes) for abdominal malignancies¹¹ and 45 minutes (40-70 minutes) for prostate

SBRT (typically 7.25 Gy/fraction).⁶⁶ For high-field MR-guided ART of abdominal SBRT using 4D-MRI guidance, the median overall total treatment was ~62 minutes using an adapt-to-shape workflow.⁶⁹ For an online adapt-to-shape prostate SBRT (35 Gy/5 fraction) workflow, a median fraction treatment time of 50 minutes (range, 46-65) has been reported.⁷⁰

Pretreatment plan and delivery QA

Offline ART strategies follow treatment planning and delivery QA procedures that are standard of practice. Online ART, on the other hand, requires plan and delivery checks to be performed in an accelerated timeframe. At present, commercially available options are limited; thus, many groups are developing in-house QA tools. One such example is for MR-guided ART in which a software program reads DICOM data from the base and daily adapted plan and compares the beam angles, number of segments, beam-on time, fluence patterns, and volumes (initial vs replanned).⁷¹ An independent secondary dose calculation was also developed to ensure the adapted plan's integrity before treatment. Another in-house QA tool built in C++ can be used for conventional and MR-guided linacs and checks demographics, imaging information (ie, patient orientation, electron density), contour integrity, monitor units, MLCs and jaws within machine specifications, and dose calculation accuracy.⁷² The MRIdian Linac (ViewRay Inc, Mountain View, CA) has a vendor-provided online adaptive QA tool that runs on the treatment console and performs a rapid secondary dose calculation of the new adapted treatment plan. A report is automatically generated with plan comparisons, 3D




Fig. 2. Deformable image registration is used in many aspects of the adaptive radiation therapy (ART) workflow, including contour propagation and density redistribution. Note the deformed right kidney and erroneously warped deformed density map highlighting the need for per-fraction review and quality assurance of the electron density map and contours used for online ART. *Abbreviations:* LT = left; PTV = planning target volume; RT = right.

gamma analysis, contour/dose statistics, and per-beam fluence comparisons. ART workflows may integrate third-party independent dose calculation and adaptive plan QA, such as the Varian Ethos system that uses the Mobius QA platform.³³ Other commercial options are emerging or are being customized that provide independent dose calculation checks, such as MU2Net and RadCalc. Ideally, automated plan checks and secondary dose calculation tools would perform an independent evaluation of plan quality; however, these are still works in progress for many vendors and remain an unmet need.

Dose reporting

A methodology for dose reporting is also required to ensure homogeneity across clinical trial study sites. For example, the protocol could state that full OAR delineation is required (whether in real time or postdelivery) or that a more limited delineation scheme (ie, a few centimeters from the PTV) can be performed to facilitate more rapid contouring for online dose evaluation and subsequently reviewed offline with full delineations. An alternative strategy would be to implement concepts from brachytherapy, as carried out in NRG-GY006.⁷³ Here, volume dose parameters are defined for dose tracking and reporting per ICRU Report #89.⁷⁴ In GY006, the specific reference point locations and volume definitions are well defined (ie, D2cc of the bladder, rectum, and sigmoid) and are recorded for each fraction.⁷³

Quality Assurance Needs

Deformable image registration and contour propagation benchmarking

Direct qualitative evaluation of a DIR result can be performed via what TG-132 defines as an image-image visual validation of the deformed image with respect to the stationary image, including split screen displays, region of interest overlap, overlay assessment, or side-by-side display via a linked cursor.³⁴ Many commercially available software packages include functionality to visually display DVFs that can be overlaid on the deformed data set, including incorporating color coding and vector length displays to highlight potential regions of nonphysical or erroneous deformations. Although TG-132 recommends that DIR programs be able to export a DVF in DICOM format, vendor compliance is still a work in progress. Nevertheless, to properly perform a quantitative benchmarking of DIR accuracy, appropriate physical or digital phantoms are required. Although deformable physical phantoms with implanted landmarks have been built, at present they are not widely commercially available.⁷⁵⁻⁷⁷

Benchmarking multimodality ART workflows such as MRI/CT or PET-CT/CT with physical phantoms also introduces challenges in phantom construction and landmark

visibility. The major advantage of using physical phantoms is to perform end-to-end testing in a clinical setting with consideration of the entire ART workflow. However, more straightforward DIR benchmarking can be achieved via the use of a digital phantom for comparing a user-obtained DVF generated by the DIR software with a gold-standard DVF. A digital validation set can be created in software from virtual phantoms or patient scans by generating a warped image and its associated structure set from an original image (and its associated structure set) with a known DVF.⁷⁸ Ideally, the original image and structure set, warped image and structure set, and ground-truth DVFs can all be imported to a user's DIR software for testing. Several studies have explored this approach,^{51,79} and TG-132 also provided data sets created from ImSimQA software and recommended commercial DIR software vendors to provide feasible tools for user validation.⁸⁰ TG-132 provides guidelines for DIR evaluation metrics such as setting the tolerance of point-wise registration error or mean distance to agreement between 2 surfaces to within the magnitude of the maximum voxel dimension (approximately 2-3 mm).

Yet, few commercial systems adopted by radiation oncology departments have the recommended function for importing or comparing DVF files. In this case, indirect validation metrics (eg, target registration error, DSC, mean distance to agreement) may have to be adopted for clinically feasible evaluation of DIR quality comparing propagated landmarks and structures with the ground truth.^{34,80} A detailed multi-institution evaluation of DIR commissioning and QA is currently underway by NRG Oncology to provide benchmarking guidelines for clinical trials involving DIR and ART. The testing criteria include TG-132 compliance, rigid registration accuracy, and deformable registration accuracy between the planning CT and other image modalities (CT, CBCT, PET, and MRI) for various body sites including head and neck, lung, and prostate.

Autosegmentation may also be part of an ART workflow. These contours, whether created de novo or through DIR contour propagation, should be reviewed by a radiation oncologist or other appropriately trained personnel. A rate-limiting step in the process may be reliance on a physician to recontour the relevant OARs or target. Opportunities to make this more efficient include workflows that enable safe remote contouring and viewing,⁸¹ training therapists or other auxiliary staff to perform the initial recontouring with physician approval,⁸² and systematic applications of autocontouring tools. Evaluation of the autocontouring functionality should be assessed before clinical implementation, and a protocol for the review of contours generated during online ART should be established. Ultimately, the accuracy of the final contours should be within the uncertainty of an expert contouring the structure from scratch, with a tolerance for the DSC value between 2 contours to be within the contouring uncertainty (approximately 0.8-0.9).³⁴ Generally speaking, many online ART workflows consist of rigidly copying the target volumes to the daily image in lieu of deforming or modifying the target during the online

process.¹¹ The clinical rationale for this decision is that complementary, multimodality diagnostic images as well as consultation of surgical or diagnostic reports are often used to assist in target delineation but are not typically available at the time of online replanning. For example, in a prospective clinical trial for prostate SBRT, the prostate target volume was rigidly registered to the anatomy of the day and only edited as needed, such as with rotational differences.⁶²

Dose accumulation may be used for retrospective evaluation of the delivered dose, with the verification carrying particular significance when plans are created based on images other than a conventional simulation CT (eg, dose based on a CBCT or a synthetic CT generated from MRI). Dose accumulation accuracy depends on the DIR accuracy as well as mass changes occurring during the treatment course.⁸³ Efforts are currently underway to further develop validation schemes, such as developing new methods for dose mapping,⁸⁴ using the energy conservation criterion,⁸⁵ developing uncertainty metrics,⁸⁶ and using computational⁷⁸ or deformable phantoms.^{87,88}

Machine-specific quality assurance

As is the case with non-ART workflows, the treatment machine needs to perform within specifications for reliable radiation delivery. For conventional mechanical and dosimetric assessment of machine performance, a standard QA program as described in AAPM Task Group Reports 142 is appropriate.⁸⁹ ART features an increased dependence on imaging systems in the treatment room. This underscores the need for appropriate periodic QA regarding image quality. Robust examination of factors such as geometric distortion, image artifacts, and HU-to-electron density calibration curves is necessary if the imaging system is to be used for ART replanning.

End-to-end testing of ART workflows

An end-to-end verification test should be conducted before clinical implementation of ART to evaluate the system holistically and to establish confidence in the dose delivered to the patient. To benchmark offline ART, digital phantoms such as the TG-132 test suite or POPI model can be implemented to benchmark DIR and dose accumulation depending on the imaging modality used in the workflow. For online ART, end-to-end verification should include the imaging of at least 2 geometries of a physical phantom using the modalities used in the ART workflow (eg, CT, CBCT, MRI), the clinical use of ART subsystems (eg, DIR, autocontouring, dose accumulation, and plan reoptimization), and ultimately, the comparison of cumulative delivered dose with the intended dose modeled by the treatment planning system. A verification of the secondary dose calculation or verification system should also be performed using the modified geometry. Regardless of the additional tasks and subsystems

involved in an ART workflow, the final dosimetric accuracy should be within the conventional guideline of $\pm 5\%$ of the intended dose.⁵

At present, only a few physical phantoms have been made by independent investigators to meet all these needs. Multimodality anthropomorphic pelvis phantoms that mimic internal organ kinematics have been built recently.^{88,90} Deformable lung⁹¹ and abdominal phantoms^{75,92} have also been devised and have been implemented to evaluate accumulated dose. In addition to end-to-end tests to verify the planning and delivery of an ART workflow, failure mode effects analysis may be used to characterize the ART process and to further direct efforts of the associated QA program, such as described for real-time⁹³ and online⁹⁴ ART.

Adaptive plan-specific quality assurance

For online ART, PSQA options may be limited before treatment delivery. Performing measurements on each plan can become impractical if additional plans are created frequently, and predelivery measurements may not be feasible for online workflows when the patient is on the table.⁹⁵ As a result, one must balance the practical costs of plan-specific QA while ensuring the dose delivered is safe and appropriate. In vivo portal dosimetry allows for patient-specific or transmission measurements that have been applied in several ART scenarios, including using an electronic portal imager integrated into a 1.5T MR-linac.⁹⁶ Reoptimization methods such as implementing MLC aperture morphing from a base plan as opposed to a fully generated reoptimization may lessen the likelihood of a PSQA failure. Finally, clinical trial endpoints (eg, dose that causes a specific toxicity) may need to consider the possibility that protocols will adopt limited manual recontouring of OARs within some distance of the PTV.

Generally speaking, adaptive plans should be held to a standard with prescribed clinical criteria similar to those in the original plan. AAPM Task Group Report 218 discusses techniques for plan-specific intensity modulated radiation therapy (IMRT) QA and recommends tolerance limits and action limits of 95% and 90% γ passing rates, respectively, for 3%(global)/2 mm, with a 10% dose threshold for both the perpendicular field-by-field and true composite methods.⁶ Another approach receiving increased attention is to simulate rather than measure the delivered dose. For offline workflows, machine log files generated during QA delivery of the plan with or without a phantom can be used.^{7,8} For online workflows, it may be possible to perform a dry run, in which the mechanical components of the delivery are enacted but no dose is delivered. This could be performed with the patient on the table, but with obvious caveats regarding added time and risk. Lastly, for online workflows, various systems could be used to monitor the delivered dose in real time in lieu of pretreatment QA. Machine log files can be used in this

way, retrospectively determining the fidelity of the delivered plan.⁷ Additionally, transmission detectors attached to the treatment machine or portal imaging devices may verify treatment field apertures and instantaneous output during delivery.

Although various PSQA methods are available, it remains imperative that rigorous plan-specific checks be performed before treatment, including verification of plan data integrity and plan dosimetric quality, monitoring of unit calculations, and correct data transfer from the treatment planning system to the record and verify system.⁹ Software solutions are likely to play an increasing role in verifying consistent treatment parameters and accurate data transfer in the accelerated ART workflow.¹⁰ Where feasible, QA on the deliverability of the treatment plan should be conducted before the patient's treatment. This applies to offline ART plans and to the initial treatment plan for both online ART and offline ART. Posttreatment analysis of the delivered parameters will suffice where pretreatment measurements are not feasible (eg, adapted online ART plans), provided the other checks on plan integrity and data transfer have been performed properly.^{9,11}

ART action levels and evaluation criteria

Clear ART directives are required a priori to facilitate both online or offline ART in a systematic fashion. For offline ART, directives may be based on empirical data (ie, at set time points for replanning) or practical clinical considerations (eg, weight loss, tumor volume changes, review of anatomic changes in daily setup images, treatment breaks, or ill-fitting immobilization devices). Example online ART objectives may include violations of predetermined OAR dose limits or target dose coverage considerations, although it is important to note that these should be evaluated using the dose expected on the geometry and delineated organs of the day.

Daily planning objectives will often be similar to those used for generation of the initial plan and, whenever possible, should be prespecified and imported into the treatment planning system to minimize time required for adaptive plan generation.

To facilitate routine practice of offline ART, an automated dose-volume evaluation based on the daily treatment fraction would be ideal. The PreciseART tool (Accuray) is a semiautomated tool that initiates the dose-volume evaluation process as soon as each fraction delivery is completed.⁶⁰ The tool automatically creates the merged daily and plan images, deforms the plan contours, calculates dose on the daily image, accumulates the daily dose onto the planning CT, and generates a structured report with dose-volume data, user-defined metrics, flags, trends, and triggers for ART. The plan reviewer can thus identify at a glance whether a particular dose-volume objective is no longer being met and if an adaptive plan is needed based on a predefined action level for future fractions.

For online ART, a solution to automatically and objectively determine when online ART is required immediately after the acquisition of the daily image is highly desirable. For example, Lim et al reported a method to rapidly determine the need for online ART by analyzing the Jacobian determinant histogram obtained from the DIR between the plan and daily images without time-consuming and labor-intensive structure delineation based on the daily image.⁹⁷ The recently introduced iterative CBCT-based online ART platform incorporates guided clinical decision-making at several steps in the ART process, including image approval, autocontouring, and plan approval.³³ It is anticipated that rapid evaluation solutions will be an active area of development.

Summary of minimum requirements and recommendations

Table 3 provides a summary of minimum elements and QA requirements to integrate ART into clinical trials, with associated rationale provided for potential clinical impact.

Currently, the most comprehensive benchmarking of ART was that implemented by the Trans Tasman Radiation Oncology Group for a multi-institutional clinical trial of ART for bladder cancer.⁹⁸ The ART schema consisted of delivery of a conventional plan for the first 7 days of treatment, with the remainder of the treatment delivered using 1 of 3 plan options with varied bladder-filling conditions. The 3 different plans were generated based on a hybrid of the original planning CT and 5 CBCT bladder volumes acquired during the first week of treatment. Credentialing consisted of the following: (1) a facility questionnaire, (2) a treatment planning exercise, and (3) a site visit, including a phantom-based implementation of image guidance. For clinical treatments, the presence of a trained team member was required during daily IGRT. The training of this individual consisted of a 1-day course or an e-Learning module. The treatment planning exercise included the delineation of structures and the generation of plans with varied treatment planning margins based on the union of contours generated from several treatment fractions. Of interest is the on-site visit by trial coordinators, which included discussions, lectures, review of the planning exercise, and past clinical CBCT data sets, as well as a mimicked ART workflow procedure. Here, treatment planning was conducted on digital phantom data with an initial bladder-filling condition, and IGRT and ART plan selection were performed based on differing anatomy. Dosimetric verification with thermoluminescent dosimeters was also conducted.

Another such example of multi-institutional implementation and credentialing for ART clinical trials is the Radiotherapy Trials Quality Assurance group, which has coordinated efforts across 10 centers and 71 radiation therapists in the United Kingdom.⁹⁹ Here, real patient data were used for credentialing, including contouring,

Table 3 Summary of minimum requirements to consider for ART workflow components

ART component	Element	Suggested minimum requirement	Potential clinical impact
Imaging	HU accuracy	CT number accuracy within 10%	20% variation in HU value may result in a systematic dose error of 1.5% ⁹⁴
	Geometric integrity	≤1 mm (within 10 cm radial distance of isocenter) ≤2 mm (>10 cm radial distance away from isocenter) ⁹⁵	Inaccurate localization of organs Inaccuracies in dose calculation
	Low contrast resolution	Per AAPM TG recommendations for the ART planning modality	Limited boundary detection that may adversely affect accurate delineation
	Consistent physiological state as reference data set (breath-hold/internal filling)	Motion managed within TG-76 recommendations (<5 mm) ⁹⁶	Over-/underestimate of target/OAR doses Incorrect state of internal anatomy for treatment planning
	FOV	Contains all relevant anatomy and full integrity skin contour	Inaccurate dose calculation for missing anatomy Lack of one-to-one correspondence may lead to erroneous deformable image registration
	Artifacts	ART planning image shall be free of artifacts in the clinically usable FOV	May obscure relevant anatomy Delineation accuracy adversely affected Dose calculation may be adversely affected
Image registration	Deformable registration	Visual assessment Point-wise registration error or mean distance to agreement within magnitude of maximum voxel dimension ³⁹	Erroneous deformations may warp images, leading to inaccurate geometry and underlying electron densities
	Contour propagation	Visual assessment Dice similarity coefficient >0.8 ³⁹	Inaccurate dose evaluation due to incorrect target volumes Under- or overestimated volumes
End-to-end/workflow testing	Localization using clinically applicable ART workflows and imaging modalities	Data integrity verified via TG-53 ⁹⁷ Concordance of external laser system/landmarks: Preferred: 1 mm Acceptable: 2 mm	Localization uncertainties Input/output discrepancies Systematic offsets introduced
	Dosimetric accuracy	±5% of intended dose ⁵	Inaccurate dose evaluation

Abbreviations: ART = adaptive radiation therapy; CT = computed tomography; FOV = field of view; HU = Hounsfield unit; OAR = organ at risk.

treatment planning, IGRT, the plan selection process, and rapid review of the first enrolled patient. Overall, the credentialing process tested the main components of the trial ART workflow, including hardware and software, and included the decision-making process. This broad benchmarking underscores the fact that ART is dependent not only technology but also on workflow and procedure. For that reason, both preimplementation and periodic QA need to evaluate the technique from a comprehensive perspective.

Personnel Recommendations

Online ART physician directive and approval

Regardless of ART approach, the attending physicians must first specify quantitative adaptation criteria based on a physician directive to determine the necessity of adaptive replanning. Typical components include the structures to be recontoured, OAR volumetric constraints, and minimum

target coverage criteria subject to the OAR constraints. If all OAR constraints are met owing to favorable geometry, another ART action criterion may be target coverage improvement above a certain threshold, such as >10%, compared with the original plan.

When online ART is anticipated, substantial physician involvement may be required and analogous to that required for nonadaptive or offline treatment planning, but with increased time constraints for online ART. For online ART, physician approval may be required for patient localization and positioning, which is analogous to approval of simulation in the offline setting. Subsequent delineation and thorough review of target and OAR segmentation are required to evaluate the need for online adaptation and facilitate plan reoptimization if clinically indicated. Similar to offline ART processes, review and approval are required for target and OAR segmentation before replanning, with objectives provided for target coverage and OAR sparing.

Although physicians often participate in this process, recent efforts have been implemented to train radiation

therapists or other staff members to perform contouring.⁸¹ Ultimately, if a new plan is found to be justified based on predefined clinical criteria, documented physician approval of the new plan and associated QA is required to confirm the adapted prescribed dose, volume, and technique and to document any planned escalation or de-escalation in the prescribed target dose based on the patient anatomy of the day. In the context of clinical trial implementation, the physician directive should also include the objective indication for ART to generate data regarding prevalence of specific ART indications.

Online ART tasks and responsibilities

An online ART workflow can be best described as a choreographed process involving contributions from several team members, including radiation therapists, medical physicists, and physicians, with typical roles as outlined in Table 4. An example low-field online MRgART workflow is described because it has been previously published in several clinical trials,^{11,20,48} with similar workflows also being reported for high-field MRgART.¹⁰⁰

First, the radiation therapists bring the patient into the room, perform initial setup, and acquire a volumetric MRI suitable for target alignment and with a large enough FOV to facilitate online treatment planning. The radiation therapist then aligns the treatment target in the image guided radiation therapy workspace and pages the covering physician and adaptive planner (typically a physicist or dosimetrist). Deformable registration-based auto-segmentation is initiated, followed by manual edits of autogenerated critical structure contours. Critical structure contours may be edited by the adaptive planner and may be reviewed by the covering physician or other qualified personnel. The gross tumor volume is rigidly propagated (not deformed) and may be edited by the covering physician as deemed necessary. Derived structures, such as PTV expansions or optimization volumes, are generated based

on predetermined workflows that can be rapidly applied online. Dose is then recalculated on an electron density data set derived from registration of the initial plan's electron density to the daily setup image. The "predicted dose," or the dose that would have been delivered if the plan were not adapted, is then evaluated using dose-volume histograms based on the new anatomy and recontoured structures. Based on the predicted dose, the current anatomy visualized in the setup image, and predetermined clinical criteria, a decision is made whether to treat as-is or to adapt.

Attending physicians specify quantitative adaption criteria per plan based on a physician-directive planning sheet that are then used to determine the necessity of adaptive replanning. If the decision is made to adapt, in one example online workflow, IMRT optimization is performed with the same structure weights and beam angles as the offline plan (only the structures themselves, and the electron density map, having changed). Beam angles and structure weights can be edited if needed, but they usually are not edited because of the corresponding increase in time required. Dosimetry of the adaptive plan is evaluated and a decision is made whether to treat the adaptive plan, treat the initial plan, or abort the fraction. Finally, gating parameters are set, if applicable, and the treatment is initiated.

Offline ART physician directive and approval

Offline ART is often triggered by clinical observations such as loose-fitting masks, patient weight loss, or changes observed over time on volumetric on-board imaging such as CBCT. One such example is highlighted in Figure 3 for a patient with stage III cT3N2cM0 nasopharyngeal carcinoma who was scheduled to receive 70 Gy in 33 fractions with concurrent chemotherapy. Major reductions in the primary tumor and bilateral neck nodes were observed on the CBCT by the 12th fraction and a weight loss of ~10 lb was also observed, prompting a resimulation and new plan generation. DIR was conducted between the initial TPCT

Table 4 Example online adaptive workflow actions and potential corresponding staff roles

Action	Therapist	Dosimetrist	Physicist	Physician
Acquire setup imaging and align patient	●		✓	✓
Critical structure recontouring		●	●	✓
Gross tumor volume contour, as needed		✓	✓	●
Create derived contour structures		●	●	✓
Preadaptation evaluation		✓	✓	●
Plan reoptimization		●	●	✓
Plan evaluation		✓	✓	●
Quality assurance checks			●	✓
Configuration of gating and beam-on	●		✓	✓

● Performed by

✓ Reviewed by

Roles may be adjusted based on internal credentialing processes.




Fig. 3. Patient with stage III cT3N2cM0 nasopharyngeal carcinoma who underwent an offline adaptive replan due to volume reductions in the primary tumor and bilateral neck nodes. (A) Initial planning computed tomography (CT) scan at the level of the maximum extent of the primary nasopharyngeal cancer; (B) resimulation CT scan at fraction 12 showing a major reduction in the primary tumor volume, with the original extent of the primary tumor in red; (C) resultant deformation map at the level of the primary tumor; (D) initial planning CT scan at the level of the neck nodes; (E) resimulation CT scan (fraction 12) at the level of the neck nodes showing the original extent of the neck nodes outside of the external anatomy; and (F) resultant deformation map at the level of the neck nodes. Scale shown is the 3D vector displacement in millimeters. (A color version of this figure is available at <https://doi.org/10.1016/j.ijrobp.2020.10.021>.)

and the resimulation CT using a Demons-based algorithm (SmartAdapt, version 13.0, Varian Medical Systems). Local regions of deformation and tumor regression can be observed.

In offline ART settings, requests are often made ad hoc by the physician and documented in the electronic chart. However, to implement offline ART more systematically in

clinical trials, more rigid criteria are required, such as defining a predetermined timepoint (eg, after an initial dose or specific fraction⁵⁷) or using a geometric constraint (ie, for a head and neck trial when GTV shrinkage exceeded 2 mm via weekly imaging).⁵⁸ The offline directive should include the adaptive criteria, dose limits of the plan summation (either rigid or deformable as validated by the physics team), and physician approval of the final plan.

Efficiency Recommendations

Frequency of plan adaptation

In an ART workflow, the frequency of plan adaptation can have many practical and dosimetric ramifications. In principle, increasing the frequency with which plans are adapted to changes in patient position, anatomy, and dose will maintain or improve the clinical goals of treatment, including the therapeutic ratio. However, the dosimetric improvement—and therefore the cost-benefit ratio—of increasingly frequent adaptation is dependent on the clinical context and may exhibit diminishing returns.¹⁰¹ Specifically, increasing the frequency of adaptation when OARs are anatomically stable and tumor response occurs during the course of weeks may result in a decreasing incremental benefit and increasing use of clinical resources, as has been demonstrated in lung cancer treatment planning studies.³ In contrast, daily online adaptation has been shown in a prospective clinical trial to allow substantial simultaneous dose escalation and OAR sparing for abdominal SBRT, in which daily anatomic variation both in tumor and OAR anatomy is present.⁴ The optimal timing and frequency of adaptation therefore depends on anatomic changes characteristic of the treatment site, the time interval of anatomic change, and the proximity of a given target or an OAR to a steep dose gradient. These factors, in conjunction with the increased workload of repeating plan preparation steps such as contouring, optimization, and verification, affect the optimal frequency of ART. In the context of clinical trial implementation, it is important to clarify the specific goal of adaptation, with objective action thresholds to allow multi-institutional uniformity of the adaptive technique. For example, if anatomic change results in violation of a previously defined OAR constraint or coverage goal, adaptive replanning may be objectively warranted.

Offline optimization and replanning

For disease sites in which anatomic changes occur gradually (over the course of several treatment fractions), offline optimization is generally preferred to online ART owing to greater flexibility in time constraints and less required personnel. Definitive head and neck radiation therapy is a scenario in which the anatomy exhibits small changes that trend during the course of treatment. Examples include the




Fig. 4. An example of initial (left) and adaptive (right) radiation therapy treatment plans from RTOG 1106. The initial plan was based on pretreatment positron emission tomography (PET) and computed tomography (CT) target volumes and treated to 46.2 Gy in 21 fractions (Fx). The adaptive plan was designed to boost the residual CT and PET volumes based on during-treatment imaging. The boost dose was prescribed up to 3.8 Gy/Fx, limited by normal tissue constraints. PET volumes were based on autothresholding, and dose summation was performed on the initial planning CT using rigid registration. Figure credit: Martha Matuszak, PhD. *Abbreviations:* GTV = gross tumor volume; PTV = planning target volume.

decrease in volume and movement toward the midline of head and neck tumors.⁵ This pattern of change suggests that an ART workflow focused on occasional offline adjustments in response to the observed anatomic trends is appropriate, but it must be based on objective criteria of decreased target coverage or clinically impactful increases in OAR dose. Offline ART is also appropriate when the adaptation is determined based on imaging findings that are available sufficiently in advance of the planned adaptation. This generally is the case when adaptation is based on planned interim imaging assessments, as was performed in the RTOG 1106 trial using FDG-PET/CT-based adaptation for lung cancer as shown in Figure 4.

Online optimization and replanning

Online ART offers greater theoretical benefit for clinical scenarios in which significant random interfraction anatomic change occurs, in particular when the change corresponds to a region with a steep dose gradient. In prostate radiation therapy, large random changes such as bladder and rectal filling can affect the delivered dose. Because of the random nature of these changes, online corrections may be more appropriate for maintaining the desired dose distribution than offline corrections intended to address trending changes.^{6,7} Furthermore, intrafractional changes may occur on the timescale of an individual treatment fraction, so the duration of the imaging and replanning effort is of particular concern. A potential benefit of online ART has also been suggested for abdominal SBRT, which provides a similar clinical scenario of random interfractional changes, including variable OAR position along a high-dose gradient and high dose per

fraction, all of which may significantly affect the delivered dose and associated toxicity risk.⁸

Example ART implementation for cancer sites

Appendix E1 highlights key evidence outlining the potential clinical benefits for major cancer disease sites. Considerations were given for online, offline, prospective, and retrospective trials with clinical and dosimetric endpoints summarized.

Specialty ART planning considerations

Proton therapy

Because of the sensitivity of protons to interfractional uncertainties relative to that of photons, ART is particularly advantageous for proton therapy. In a retrospective study of advanced non-small cell lung cancer, 61% of patients replanned with intensity modulated proton therapy would have required adaptation during treatment owing to anatomic changes.¹⁰² For online adaptive proton therapy, CBCT has been implemented with postprocessing corrections to correct for the Hounsfield numbers because small inaccuracies may lead to large-range uncertainties.¹⁰³ An ART proton therapy workflow has been described that generates a virtual CT scan (derived from CBCT coupled with DIR) to produce more accurate CT numbers and improved image quality for replanning.¹⁰⁴ Mobile helical CT has also been implemented for online ART proton planning to produce high-quality data sets in the ART process.¹⁰⁵ Further reduction of the range uncertainty is currently being investigated at multiple institutions,¹⁰⁶ but

as of yet, they do not appear to be available in the treatment room, which will only permit offline adaptive regimens.

Brachytherapy

Brachytherapy is perhaps one of the most conformal and adaptive approaches to deliver dose to a defined target. With the advent of the GEC ESTRO guidelines¹⁰⁷ outlining the definition of a GTV, high-risk CTV, and intermediate-risk CTV on MRI at the time of cervical brachytherapy, as well as the recent ICRU 69 Report¹⁰⁸ further elaborating on volumetric brachytherapy, we have moved from film-based point dosimetry to volume-based brachytherapy for both the targets and the adjacent OARs. Brachytherapy is now referred to as image guided adaptive brachytherapy.¹⁰⁹ With the advent of CT and MR-compatible applicators as well as sophisticated 3D digital images, radiation plans can be generated on these images with the applicators in place. This reveals the doses to key volumes of these targets as well as the OARs so that modifications can be made to enhance target coverage and decrease dose to the critical organs. Manipulation of dwell times and positions and use of interstitial and intracavitary applicators can be done for each fraction to optimally balance these competing dose constraints. Given that usually 4 to 5 fractions are delivered for cervical cancer, each implant offers a new opportunity to adapt the dose distribution. This has led to a decrease in complications and an increase in both local control and survival that parallel and exceed the impact of concurrent chemotherapy.¹⁰⁹⁻¹¹¹ Combining the doses delivered with external beam and brachytherapy remains a challenge, and a dedicated working group has been formed at NRG to address this topic. Current state of the art uses an EQD2 worksheet (downloadable at:

https://www.americanbrachytherapy.org/ABS/assets/file/public/consensus-statements/gyn_HDR_BT_docu_sheets.xls), which converts both the brachytherapy and external beam doses to equivalent 2 Gy doses for dose summation. Ideally, voxel-by-voxel dose accumulation of the external beam and brachytherapy components of treatment would be implemented; however, these are currently works in progress.

Forward-Looking Statements and Unmet Needs

Isotoxic dose escalation

Isotoxic-based radiation therapy refers to treatment planning that is driven primarily by the acceptable clinical toxicity risk rather than a mandated target dose. For isotoxic planning, the target dose is escalated or de-escalated to maintain a constant, acceptable risk of clinical toxicity based on the dose to OARs. Isotoxic planning is not new, with prior implementations described for multiple disease sites including lung, prostate, and liver malignancies.²⁻⁴ Prior reports of isotoxic planning are driven by inter-patient variability assumed to remain stable during a

treatment course. In contrast, adaptive isotoxic treatment also allows treatment modification for a given patient due to anatomic changes that occur on an interfraction or intrafraction basis.

Adaptive isotoxic treatment planning has several implications that must be accounted for in the context of clinical trial implementation. First, the maximum dose believed to be of clinical benefit should be determined a priori to prevent adaptive delivery of a higher target dose than is clinically warranted when OAR anatomy is favorable. Similarly, if the relationship between target and OAR anatomy is unfavorable, investigators must decide whether a sacrifice in target coverage is truly warranted to maintain OAR isotoxicity.

In the absence of ART, application of an initial treatment plan to variable patient anatomy is known to frequently result in a dose to OARs that violates traditional hard planning constraints.¹¹² Although ART reoptimization may be performed to avoid violation of constraints, previously established dose constraints in the nonadaptive setting may not accurately reflect true OAR tolerance. Because previously established constraints are based on static OAR anatomy, it is plausible that such toxicity metrics did not account for drift of OARs into a high-dose region unknown to the clinician. Such variability may be accounted for with current ART techniques. Therefore, in the context of clinical trial implementation, the delivered dose to OARs with isotoxic planning should be carefully documented so that clinical toxicity rates observed with isotoxic ART may be verified relative to prior expected values. In addition, online adaptive therapy allows the potential to explore multiple novel facets of dose delivery, including daily alterations in dose per fraction, daily changes in dose homogeneity, and daily dose escalation or de-escalation.

Biological or functional guided ART

Traditional treatment response assessment based on tumor size and anatomic change is not always timely and does not necessarily correlate with final treatment outcome. Changes at the physiologic and molecular levels characterize the true underlying biological response to radiation treatment and usually occur much earlier than detectable morphologic changes. Therefore, imaging biomarkers hold great promises for adaptive radiation therapy, wherein the treatment plan can be adjusted during therapy based on individual patient's biological response. Recent studies have shown promising results of monitoring tumor biological and functional changes using the image guidance system of radiation therapy treatment machines for potential biological image guided ART.^{1,113} Recently, a prototype PET scanner coupled with a linac (ReflXion, Hayward, CA) was introduced to conduct biologically adapted radiation therapy,¹¹⁴ offering potential for PET-guided online ART in the future.¹¹⁵ To deploy these advanced techniques in clinical trials, a few key challenges need to be overcome.

Standardization of imaging acquisition protocols, measurement, and analysis methods is essential for reproducible and consistent assessment of treatment response among multiple institutions. A rigorous QA program needs to be established to allow for accurate quantification with sufficient validation. Most importantly, strategies and methods for incorporating biological information into decision-making of treatment planning need to be developed.

Integration of advanced computing

Several advancements in computing and programming offer strong potential to make both online and offline ART more efficient. One such example is the integration of a graphics processing unit that enables high processing efficiency and yields accelerated processing speeds for radiation therapy tasks at a relatively low cost.¹¹⁶⁻¹¹⁸ Many vendors have integrated graphics processing units into their clinical software solutions, often for dose calculation and treatment planning. Current major unmet needs in the online ART workflow include rapid delineation and replanning that may be improved by the integration of deep or machine learning techniques into the workflow. For example, a convolutional neural network deep learning model was trained in ~12 hours using 100 patient abdominal data sets for online MR-guided ART, generating contours in ~5 seconds with good overall accuracy.¹¹⁹ Deep and machine learning offer great potential for several other ART tasks, such as automating treatment planning via accurate dose distributions, generating high-quality planning data sets for accurate dose calculation,^{120,121} and performing automated plan quality evaluation.¹²²

Clinical trial integration

When incorporating ART into clinical trial design, the role of ART as a primary or secondary trial endpoint should be clearly defined. When characterization of ART benefit is a primary endpoint, the trial will generally be designed to report outcomes (1) from a population treated exclusively with ART in a phase 1/2 manner with descriptive clinical and toxicity outcomes or (2) in a randomized phase 2/3 setting with patients either receiving or not receiving ART based on trial randomization, with direct comparison between trial arms. Given that online ART in particular is a relatively new approach, to facilitate more rapid evaluation of ART, it may often be more feasible to incorporate ART as a secondary trial endpoint. As a secondary endpoint, ART may be incorporated or allowed for a broad spectrum of trials, in which ancillary data may be generated to characterize ART benefits in the context of a nonadaptive primary study question. For such secondary integration, use and allowance of ART is similar in concept to current trial designs, which often allow for variable planning techniques including 3D, IMRT, or proton-based treatment, depending on institutional preference.

For any trial in which ART is a primary or secondary endpoint, objective criteria that determine the specific action threshold to trigger an ART intervention are mandatory to ensure treatment uniformity. Such thresholds may be based on observed violations of initial study constraints during the ART evaluation or a prespecified improvement in target or OAR dose resulting from ART that is deemed to be clinically significant. An alternative clinical trial strategy that may implement ART as the stratification approach is to apply ART for each treatment fraction in a manner that has been reported in the literature.^{20,62,100} Another important consideration is the extent of plan review performed for ART. One institution evaluated its clinical practice of having the physicians and physicists perform a visual assessment of daily MR images without a full dose prediction for 7 pancreas patients (35 data sets) to determine the need for daily ART.¹²³ Importantly, a more thorough offline dosimetric analysis revealed that daily image review was not reliable and was insufficient to determine the benefit of ART for a patient; visual assessment only resulted in 14 of 35 fractions undergoing ART whereas 25 of 35 were revealed to have potential clinical benefit. Thus, it is recommended in an online ART clinical trial setting that daily contouring and dose prediction with a full dosimetric evaluation be performed with the appropriate time allocated for a safe and effective implementation of this process.

Given that noncompliance with radiation therapy protocol guidelines is known to correlate with inferior clinical outcomes,¹²⁴ it is imperative to verify that both physician recontouring and adaptive plan quality are in accordance with protocol recommendations. The uniformity of physician recontouring may be particularly challenging if imaging obtained for adaptive replanning does not clearly differentiate the extent of tumor response or of residual subclinical disease. Although protocol-mandated central review of physician contours and the treatment plan are widely implemented in current trials, such central review is not feasible for online ART due to the immediate nature of plan adaptation. Potential alternatives may be to develop a site-specific delineation atlas using the ART imaging modality or to require initial delineation cases for physician benchmarking. It is also recommended that a process be incorporated in the clinical trial design that before patient enrollment, in addition to physics and machine credentialing, institutional ART workflow will be confirmed. Such a process will confirm appropriate departmental workflow as per the personnel requirements section, with central review of the first ART case to include physician recontouring, adaptive planning, and appropriate evaluation regarding the clinical indication for adaptive treatment. It is also recommended that the initial (minimum 3) clinical adaptive cases for a new institution be retrospectively reviewed centrally after each adaptive fraction to ensure adherence to protocol.

Different adaptive strategies are appropriate for different treatment sites due to site-specific adaptive

radiation therapy goals and tumor and OAR characteristics. Recommendations on the range of possible adaptive frequencies and timing can be established based on estimates of inter- and intrafractional motion and their dosimetric impact.⁹ For example, plan adaptations could be triggered when the volume of the target has changed by a prespecified action threshold or when dose to an OAR exceeds a tolerance level. Such action thresholds may often be defined by the baseline coverage and OAR-sparing goals of the trial. Recommendations can also take the form of action levels based on assessments made at predetermined time points or intervals (eg, based on a single interval FDG-PET/CT as assessed in the RTOG 1106 trial or on more frequent intervals). Regardless of the details of a particular ART workflow, the timing and frequency of adaptation should balance objectively the clinical value added to the patient with considerations of the finite resources of the clinic. A template for clinical trial language supporting an online ART workflow has been provided in [Appendix E2](#), including considerations for IGRT, daily adaptation, and ART-related QA that would be added to standard treatment planning and credentialing protocols for new clinical trials.

Conclusions

Overall, although resource intensive, ART shows incredible promise for offering gains in OAR sparing and improving target coverage. As vendor offerings increase and our ability to perform workflows within standard clinical operation becomes easier, the likelihood of implementing ART more routinely—when clinically indicated—is rapidly expanding.

References

1. Yan D, Vicini F, Wong J, et al. Adaptive radiation therapy. *Phys Med Biol* 1997;42:123-132.
2. Vargas C, Yan D, Kestin LL, et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isototoxicity. *Int J Radiat Oncol Biol Phys* 2005;63:141-149.
3. Liu M, Wang Z, Zhou T, et al. Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: Long term follow-up. *Oncotarget* 2017;8:51848-51858.
4. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. *Acta Oncol* 2006;45:856-864.
5. Yan D. Adaptive radiotherapy. *Semin Radiat Oncol* 2010;20:79-146.
6. Vargas C, Martinez A, Kestin LL, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;62:1297-1308.
7. Spoelstra FO, Pantarotto JR, van Sornsen de Koste JR, et al. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: Analysis of data from a prospective clinical trial. *Int J Radiat Oncol Biol Phys* 2009;75:1092-1097.
8. Schwartz DL, Garden AS, Thomas J, et al. Adaptive radiotherapy for head-and-neck cancer: Initial clinical outcomes from a prospective trial. *Int J Radiat Oncol Biol Phys* 2012;83:986-993.
9. Li X, Quan EM, Li Y, et al. A fully automated method for CT-on-rails-guided online adaptive planning for prostate cancer intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 2013;86:835-841.
10. Ahunbay EE, Peng C, Godley A, et al. An on-line replanning method for head and neck adaptive radiotherapy. *Med Phys* 2009;36:4776-4790.
11. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. *Radiother Oncol* 2018;126:519-526.
12. El-Bared N, Portelance L, Spieler BO, et al. Dosimetric benefits and practical pitfalls of daily online adaptive MRI-guided stereotactic radiation therapy for pancreatic cancer. *Pract Radiat Oncol* 2019;9:e46-e54.
13. Li XA, Liu F, Tai A, et al. Development of an online adaptive solution to account for inter-and intra-fractional variations. *Radiother Oncol* 2011;100:370-374.
14. Liu F, Erickson B, Peng C, Li XA. Characterization and management of interfractional anatomic changes for pancreatic cancer radiotherapy. *Int J Radiat Oncol Biol Phys* 2012;83:e423-e429.
15. Court LE, Dong L, Lee AK, et al. An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. *Int J Radiat Oncol Biol Phys* 2005;62:154-163.
16. Ahunbay EE, Peng C, Holmes S, et al. Online adaptive replanning method for prostate radiotherapy. *Int J Radiat Oncol Biol Phys* 2010;77:1561-1572.
17. Mohan R, Zhang X, Wang H, et al. Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. *Int J Radiat Oncol Biol Phys* 2005;61:1258-1266.
18. Heijkoop ST, Langerak TR, Quint S, et al. Clinical implementation of an online adaptive plan-of-the-day protocol for nonrigid motion management in locally advanced cervical cancer IMRT. *Int J Radiat Oncol Biol Phys* 2014;90:673-679.
19. Henke LE, Olsen JR, Contreras JA, et al. Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: Results of a phase 1 trial. *Adv Radiat Oncol* 2019;4:201-209.
20. Bruynzeel AM, Tetar SU, Oei SS, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results. *Int J Radiat Oncol Biol Phys* 2019;105:1086-1094.
21. US National Library of Medicine. NCT03621644. Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for locally advanced pancreatic cancer. Available at: <https://clinicaltrials.gov/ct2/show/NCT03621644>. Accessed October 29, 2020.
22. Hiraoka M, Matsuo Y, Sawada A, et al. Realization of dynamic tumor tracking irradiation with real-time monitoring in lung tumor patients using a gimbaled x-ray head radiation therapy equipment. *Int J Radiat Oncol Biol Phys* 2012;84:S560-S561.
23. Pathmanathan AU, van As NJ, Kerkmeijer LGW, et al. Magnetic resonance imaging-guided adaptive radiation therapy: A “game changer” for prostate treatment? *Int J Radiat Oncol Biol Phys* 2018;100:361-373.
24. Kontaxis C, Bol G, Stemkens B, et al. Towards fast online intra-fraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac. *Phys Med Biol* 2017;62:7233.
25. Klawikowski S, Tai A, Ates O, et al. A fast 4D IMRT/VMAT planning method based on segment aperture morphing. *Med Phys* 2018;45:1594-1602.
26. Hara W, Soltys SG, Gibbs IC. CyberKnife robotic radiosurgery system for tumor treatment. *Expert Rev Anticancer Ther* 2007;7:1507-1515.

27. Schweikard A, Shiomi H, Adler J. Respiration tracking in radio-surgery. *Med Phys* 2004;31:2738-2741.
28. Ferris WS, Kissick MW, Bayouth JE, et al. Evaluation of radixact motion synchrony for 3D respiratory motion: Modeling accuracy and dosimetric fidelity. *J Appl Clin Med Phys* 2020;21:96-106.
29. Keall PJ, Nguyen DT, O'Brien R, et al. The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. *Radiother Oncol* 2018;127:6-11.
30. Matuszak MM, Kashani R, Green M, et al. Functional adaptation in radiation therapy. *Semin Radiat Oncol* 2019;29:236-244.
31. Mao W, Liu C, Gardner SJ, et al. Evaluation and clinical application of a commercially available iterative reconstruction algorithm for CBCT-based IGRT. *Technol Cancer Res Treat* 2019;18:1533033818823054.
32. Gardner SJ, Mao W, Liu C, et al. Improvements in CBCT image quality using a novel iterative reconstruction algorithm: a clinical evaluation. *Adv Radiat Oncol* 2019;4:390-400.
33. Archambault A, Boylan C, Bullock D, et al. Making on-line adaptive radiotherapy possible using artificial intelligence and machine learning for efficient daily re-planning. *Med Phys Int J* 2020;8:77-86.
34. Brock KK, Mutic S, McNutt TR, et al. Use of image registration and fusion algorithms and techniques in radiotherapy: Report of the AAPM Radiation Therapy Committee Task Group No. 132. *Med Phys* 2017;44:e43-e76.
35. Lim-Reinders S, Keller BM, Al-Ward S, et al. Online adaptive radiation therapy. *Int J Radiat Oncol Biol Phys* 2017;99:994-1003.
36. Maintz JB, Viergever MA. A survey of medical image registration. *Med Image Anal* 1998;2:1-36.
37. Viergever MA, Maintz JBA, Klein S, et al. A survey of medical image registration—Under review. *Med Image Anal* 2016;33:140-144.
38. Jaffray DA, Lindsay PE, Brock KK, et al. Accurate accumulation of dose for improved understanding of radiation effects in normal tissue. *Int J Radiat Oncol Biol Phys* 2010;76(Suppl 3):S135-S139.
39. Harcastle N, van Elmpst W, De Ruysscher D, et al. Accuracy of deformable image registration for contour propagation in adaptive lung radiotherapy. *Radiat Oncol* 2013;8:1-8.
40. Harcastle N, Tome WA, Cannon DM, et al. A multi-institution evaluation of deformable image registration algorithms for automatic organ delineation in adaptive head and neck radiotherapy. *Radiat Oncol* 2012;7:90.
41. Klein A, Andersson J, Ardekani BA, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. *Neuroimage* 2009;46:786-802.
42. Pukala J, Meeks SL, Staton RJ, et al. A virtual phantom library for the quantification of deformable image registration uncertainties in patients with cancers of the head and neck. *Med Phys* 2013;40:111703.
43. Zhong HL, Kim J, Chetty IJ. Analysis of deformable image registration accuracy using computational modeling. *Med Phys* 2010;37:970-979.
44. Vandemeulebroucke J, Rit S, Kybic J, et al. Spatiotemporal motion estimation for respiratory-correlated imaging of the lungs. *Med Phys* 2011;38:166-178.
45. Castillo R, Castillo E, Fuentes D, et al. A reference dataset for deformable image registration spatial accuracy evaluation using the COPDgene study archive. *Phys Med Biol* 2013;58:2861-2877.
46. Murphy K, van Ginneken B, Reinhardt JM, et al. Evaluation of registration methods on thoracic CT: The EMPIRE10 Challenge. *IEEE Trans Med Imaging* 2011;30:1901-1920.
47. Hansen EK, Bucci MK, Quivey JM, et al. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2006;64:355-362.
48. Luterstein E, Cao M, Lamb J, et al. Stereotactic MRI-guided adaptive radiation therapy (SMART) for locally advanced pancreatic cancer: A promising approach. *Cureus* 2018;10:e2324.
49. Yan D, Jaffray DA, Wong JW. A model to accumulate fractionated dose in a deforming organ. *Int J Radiat Oncol Biol Phys* 1999;44:665-675.
50. Veiga C, McClelland J, Moinuddin S, et al. Toward adaptive radiotherapy for head and neck patients: Feasibility study on using CT-to-CBCT deformable registration for “dose of the day” calculations. *Med Phys* 2014;41:1-12.
51. Varadhan R, Karangelis G, Krishnan K, Hui S. A framework for deformable image registration validation in radiotherapy clinical applications. *J Appl Clin Med Phys* 2013;14:192-213.
52. Zhang L, Wang Z, Shi C, et al. The impact of robustness of deformable image registration on contour propagation and dose accumulation for head and neck adaptive radiotherapy. *J Appl Clin Med Phys* 2018;19:185-194.
53. Nobnop W, Chitapanarux I, Neamin H, et al. Evaluation of deformable image registration (DIR) methods for dose accumulation in nasopharyngeal cancer patients during radiotherapy. *Radiol Oncol* 2017;51:438-446.
54. Velec M, Moseley JL, Eccles CL, et al. Effect of breathing motion on radiotherapy dose accumulation in the abdomen using deformable registration. *Int J Radiat Oncol Biol Phys* 2011;80:265-272.
55. Veiga C, Lourenco AM, Moinuddin S, et al. Toward adaptive radiotherapy for head and neck patients: Uncertainties in dose warping due to the choice of deformable registration algorithm. *Med Phys* 2015;42:760-769.
56. Hugo GD, Cao K, Guy C, et al. Measurement of local deformation due to lung tumor response to radiation therapy. In: The Fifth International Workshop on Pulmonary Image Analysis. Scotts Valley, CA: CreateSpace; 2013. p. 97-108.
57. Kong F, Machtay M, Bradley J, et al. RTOG 1106/ACRIN 6697: Randomized phase II trial of individualized adaptive radiotherapy using during treatment FDG-PET CT and modern technology in locally advanced non-small lung cancer (NSCLC). Available at: <https://clinicaltrials.gov/ct2/show/NCT01507428>. Published 2012. Accessed December 1, 2020.
58. Bahig H, Yuan Y, Mohamed ASR, et al. Magnetic resonance-based response assessment and dose adaptation in human papilloma virus positive tumors of the oropharynx treated with radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. *Clin Transl Radiat Oncol* 2018;13:19-23.
59. Nijkamp J, Pos FJ, Nuver TT, et al. Adaptive radiotherapy for prostate cancer using kilovoltage cone-beam computed tomography: First clinical results. *Int J Radiat Oncol Biol Phys* 2008;70:75-82.
60. Kainz SL, Lim S, Chen G-P, et al. PreciseART adaptive radiation therapy software: Dose monitoring, re-planning, and delivery verification. Available at: https://www accuray.com/wp-content/uploads/ap-preciseart_froedtert_wp-mkt-txplg-0917-0052.pdf. Accessed October 30, 2020.
61. Olberg S, Green O, Cai B, et al. Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer. *Radiat Oncol* 2018;13:1-8.
62. Bohoudi O, Bruynzeel AME, Senan S, et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. *Radiother Oncol* 2017;125:439-444.
63. van Dijk LV, Van den Bosch L, Aljabar P, et al. Improving automatic delineation for head and neck organs at risk by deep learning contouring. *Radiother Oncol* 2020;142:115-123.
64. Boldrini L, Bibault J-E, Masciocchi C, et al. Deep learning: A review for the radiation oncologist. *Front Oncol* 2019;9:977.
65. Winkel D, Bol GH, Kiekebosch IH, et al. Evaluation of online plan adaptation strategies for the 1.5 T MR-linac based on “First-In-Man” treatments. *Cureus* 2018;10:e2431.
66. Tetar SU, Bruynzeel AM, Lagerwaard FJ, et al. Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. *Phys Imaging Radiat Oncol* 2019;9:69-76.

67. Werensteijn-Honingh AM, Kroon PS, Winkel D, et al. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. *Radiother Oncol* 2019;134:50-54.
68. Roach M, Glide-Hurst CK. MRI at the time of external beam treatment. In: MRI for Radiotherapy. New York, NY: Springer; 2019. p. 169-188.
69. Paulson ES, Ahunbay E, Chen X, et al. 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-linac: Implementation and initial clinical experience. *Clin Transl Radiat Oncol* 2020;23:72-79.
70. Cuccia F, Mazzola R, Nicosia L, et al. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. *Radiat Oncol* 2020;15:1-9.
71. Acharya S, Fischer-Valuck BW, Kashani R, et al. Online magnetic resonance image guided adaptive radiation therapy: First clinical applications. *Int J Radiat Oncol Biol Phys* 2016;94:394-403.
72. Chen GP, Ahunbay E, Li XA. Technical note: Development and performance of a software tool for quality assurance of online replanning with a conventional linac or MR-linac. *Med Phys* 2016;43:1713.
73. Leath C, Mell L, Mackay H. NRG-GY006: A randomized phase ii trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer. Available at: <https://clinicaltrials.gov/ct2/show/NCT02466971>. Published 2018. Accessed December 1, 2020.
74. [No authors listed] Prescribing, recording, and reporting brachytherapy for cancer of the cervix. *J ICRU* 2013;13:NP.
75. Liao Y, Wang L, Xu X, et al. An anthropomorphic abdominal phantom for deformable image registration accuracy validation in adaptive radiation therapy. *Med Phys* 2017;44:2369-2378.
76. Kirby N, Chuang C, Pouliot J. A two-dimensional deformable phantom for quantitatively verifying deformation algorithms. *Med Phys* 2011;38:4583-4586.
77. Graves YJ, Smith AA, McIlvena D, et al. A deformable head and neck phantom with in-vivo dosimetry for adaptive radiotherapy quality assurance. *Med Phys* 2015;42:1490-1497.
78. Stanley N, Glide-Hurst C, Kim J, et al. Using patient-specific phantoms to evaluate deformable image registration algorithms for adaptive radiation therapy. *J Appl Clin Med Phys* 2013;14:177-194.
79. Kim H, Park SB, Monroe JJ, et al. Quantitative analysis tools and digital phantoms for deformable image registration quality assurance. *Technol Cancer Res Treat* 2015;14:428-439.
80. Brock KK, Mutic S, McNutt TR, et al. Use of image registration and fusion algorithms and techniques in radiotherapy: Report of the AAPM Radiation Therapy Committee Task. *Med Phys* 2017;44:E43-E76.
81. Price A, Kim H, Henke LE, et al. Implementing a novel remote physician treatment coverage practice for adaptive radiotherapy during the coronavirus pandemic. *Adv Radiat Oncol* 2020;7:37-742.
82. Hales RB, Rodgers J, Whiteside L, et al. Therapeutic radiographers at the helm: Moving towards radiographer-led MR-guided radiotherapy. *J Med Imaging Radiat Sci* 2020;51:364-372.
83. Zhong H, Chetty IJ. Caution must be exercised when performing deformable dose accumulation for tumors undergoing mass changes during fractionated radiation therapy. *Int J Radiat Oncol Biol Phys* 2017;97:182-183.
84. Li HS, Zhong H, Kim J, et al. Direct dose mapping versus energy/mass transfer mapping for 4D dose accumulation: Fundamental differences and dosimetric consequences. *Phys Med Biol* 2013;59:173-188.
85. Li S, Glide-Hurst C, Lu M, et al. Voxel-based statistical analysis of uncertainties associated with deformable image registration. *Phys Med Biol* 2013;58:6481-6494.
86. Takemura A, Nagano A, Kojima H, et al. An uncertainty metric to evaluate deformation vector fields for dose accumulation in radiotherapy. *Phys Imaging Radiat Oncol* 2018;6:77-82.
87. Bohoudi O, Lagerwaard FJ, Bruynzeel AM, et al. End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom. *Radiother Oncol* 2019;141:200-207.
88. Cunningham JM, Barberi EA, Miller J, et al. Development and evaluation of a novel MR-compatible pelvic end-to-end phantom. *J Appl Clin Med Phys* 2019;20:265-275.
89. Klein EE, Hanley J, Bayouth J, et al. Task Group 142 report: Quality assurance of medical accelerators. *Med Phys* 2009;36:4197-4212.
90. Niebuhr NI, Johnen W, Echner G, et al. The ADAM-pelvis phantom—An anthropomorphic, deformable and multimodal phantom for MRgRT. *Phys Med Biol* 2019;13:04NT05.
91. Zhong H, Adams J, Glide-Hurst C, et al. Development of a deformable dosimetric phantom to verify dose accumulation algorithms for adaptive radiotherapy. *J Med Phys* 2016;41:106-114.
92. Ehrbar S, Jöhl A, Kühni M, et al. ELPHA: Dynamically deformable liver phantom for real-time motion-adaptive radiotherapy treatments. *Med Phys* 2019;46:839-850.
93. Sawant A, Dieterich S, Svatos M, et al. Failure mode and effect analysis-based quality assurance for dynamic MLC tracking systems. *Med Phys* 2010;37:6466-6479.
94. Noel CE, Santanam L, Parikh PJ, et al. Process-based quality management for clinical implementation of adaptive radiotherapy. *Med Phys* 2014;41:081717.
95. Green OL, Henke LE, Hugo GD. Practical clinical workflows for online and offline adaptive radiation therapy. *Semin Radiat Oncol* 2019;29:219-227.
96. Torres-Xirau I, Olaciregui-Ruiz I, Baldivinsson G, et al. Characterization of the a-Si EPID in the unity MR-linac for dosimetric applications. *Phys Med Biol* 2018;63:025006.
97. Lim SN, Ahunbay EE, Nasief H, et al. Indications of online adaptive replanning based on organ deformation. *Pract Radiat Oncol* 2020;10:e95-e102.
98. Kron T, Pham D, Roxby P, et al. Credentialing of radiotherapy centres for a clinical trial of adaptive radiotherapy for bladder cancer (TROC 10.01). *Radiother Oncol* 2012;103:293-298.
99. Tsang Y, Baker A, Patel E, et al. A new era for clinical trial quality assurance: A credentialing programme for RTT led adaptive radiotherapy. *Tech Innov Patient Support Radiat Oncol* 2018;5:1-2.
100. Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy: The Elekta Unity MR-linac concept. *Clin Transl Radiat Oncol* 2019;18:54-59.
101. Wu Q, Chi Y, Chen PY, et al. Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. *Int J Radiat Oncol Biol Phys* 2009;75:924-932.
102. Hoffmann L, Alber M, Jensen MF, et al. Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. *Radiother Oncol* 2017;122:400-405.
103. Park YK, Sharp GC, Phillips J, et al. Proton dose calculation on scatter-corrected CBCT image: Feasibility study for adaptive proton therapy. *Med Phys* 2015;42:4449-4459.
104. Landry G, Nijhuis R, Dedes G, et al. Investigating CT to CBCT image registration for head and neck proton therapy as a tool for daily dose recalculation. *Med Phys* 2015;42:1354-1366.
105. Sun B, Yang D, Lam D, et al. Toward adaptive proton therapy guided with a mobile helical CT scanner. *Radiother Oncol* 2018;129:479-485.
106. Mohan R, Das IJ, Ling CC. Empowering intensity modulated proton therapy through physics and technology: An overview. *Int J Radiat Oncol Biol Phys* 2017;99:304-316.
107. Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of

- 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006;78:67-77.
108. Griffith R, Bergmann H, Fry FA, et al. Report 69. *J Intl Comm Radiat Units Measure* 2016;3.
 109. Potter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. *Clin Transl Radiat Oncol* 2018;9:48-60.
 110. Sturdza A, Potter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. *Radiother Oncol* 2016;120:428-433.
 111. Fokdal L, Sturdza A, Mazon R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. *Radiother Oncol* 2016;120:434-440.
 112. Henke L, Kashani R, Yang D, et al. Simulated online adaptive magnetic resonance-guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: Characterization of potential advantages. *Int J Radiat Oncol Biol Phys* 2016;96:1078-1086.
 113. Hunt A, Hansen V, Oelfke U, et al. Adaptive radiotherapy enabled by MRI guidance. *Clin Oncol* 2018;30:711-719.
 114. Mazin S, Nanduri A, inventors. US patent app. 16/834,956, assignee. Systems and methods for use in emission guided radiation therapy. 2020.
 115. Crehange G, Soussan M, Gensanne D, et al. Interest of positron-emission tomography and magnetic resonance imaging for radiotherapy planning and control. *Cancer Radiother* 2020;24:398-402.
 116. Jia X, Ziegenhein P, Jiang SB. GPU-based high-performance computing for radiation therapy. *Phys Med Biol* 2014;59:R151.
 117. Men C, Jia X, Jiang SB. GPU-based ultra-fast direct aperture optimization for online adaptive radiation therapy. *Phys Med Biol* 2010;55:4309.
 118. Han X, Hibbard LS, Willcutt V. GPU-accelerated, gradient-free MI deformable registration for atlas-based MR brain image segmentation. *IEE Comp Soc Conf Comp Vision Pattern Recog Workshops* 2009;1:204-211.
 119. Fu Y, Mazur TR, Wu X, et al. A novel MRI segmentation method using CNN-based correction network for MRI-guided adaptive radiotherapy. *Med Phys* 2018;45:5129-5137.
 120. Liang X, Chen L, Nguyen D, et al. Generating synthesized computed tomography (CT) from cone-beam computed tomography (CBCT) using CycleGAN for adaptive radiation therapy. *Phys Med Biol* 2019;64:13.
 121. Li Y, Zhu J, Liu Z, et al. A preliminary study of using a deep convolution neural network to generate synthesized CT images based on CBCT for adaptive radiotherapy of nasopharyngeal carcinoma. *Phys Med Biol* 2019;64:12.
 122. Jarrett D, Stride E, Vallis K, et al. Applications and limitations of machine learning in radiation oncology. *Br J Radiol* 2019;92:20190001.
 123. Tyran M, Jiang N, Cao M, et al. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. *Radiother Oncol* 2018;319-325.
 124. Ohri N, Shen X, Dicker AP, et al. Radiotherapy protocol deviations and clinical outcomes: A meta-analysis of cooperative group clinical trials. *J Natl Cancer Inst* 2013;105:387-393.